1-3 of 3
Emilie Routier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1

Caroline Robert, Céleste Lebbé, Thierry Lesimple, Eija Lundström, Valérie Nicolas, Bruno Gavillet, Philippa Crompton, Barouyr Baroudjian, Emilie Routier, Ferdy J. Lejeune
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (5): 858–865.
https://doi.org/10.1158/1078-0432.CCR-22-2812
Published: 01 March 2023
View articletitled, Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Open the PDF for Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1 in another window
Includes: Supplementary data
Journal Articles

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

Isabelle Girault, Julien Adam, Shensi Shen, Séverine Roy, Caroline Brard, Sara Faouzi, Emilie Routier, Jéremy Lupu, Sarah Warren, Kristina Sorg, SuFey Ong, Pascale Morel, Jean-Yves Scoazec, Stéphan Vagner, Caroline Robert
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 518–525.
https://doi.org/10.1158/1078-0432.CCR-21-1229
Published: 01 February 2022
View articletitled, A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Open the PDF for A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4806–4819.
https://doi.org/10.1158/1078-0432.CCR-12-0742
Published: 30 August 2012
View articletitled, First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Open the PDF for First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors in another window
Includes: Supplementary data